专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明公开

EP1555318A3 Hematopoietic cytokine receptor 失效
标题翻译：造血细胞因子受体
公开(公告)号：EP1555318A3
公开(公告)日：2008-10-08
申请号：EP04030182.2
申请日：1997-05-19
申请人： ZymoGenetics, Inc.
发明人： Baumgartner, James W. , Foster, Donald C. , Grant, Francis J. , Sprecher, Cindy A.
IPC分类号： C12N15/12 , C07K14/715 , C12N15/62 , C07K16/28 , G01N33/68
CPC分类号： C07K14/715 , A61K38/00 , C07K2319/00
摘要： Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular ligand-binding domain of a cell-surface receptor that is expressed at high levels in lymphoid tissues, including B-cells and T-cells. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of lymphoid and myeloid cells in vitro and in vivo . Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo .

12. 发明公开

EP1881070A2 Human cytokine as ligand of the zalpha receptor and uses thereof 有权
标题翻译： Menschliche Zytokine als Liganden des Z-Alpha-Rezeptors und Verwendungen davon
公开(公告)号：EP1881070A2
公开(公告)日：2008-01-23
申请号：EP07017344.8
申请日：2000-03-09
申请人： Zymogenetics, Inc.
发明人： Novak, Julie E. , Sprecher, Cindy A. , Gross, Jane A. , Nelson, Andrew J. , Dillon, Stacey R. , Hammond, Angela K.
IPC分类号： C12N15/19 , C07K14/52 , C12N15/62 , C12N15/85 , C07K16/24 , C12Q1/68 , G01N33/68 , A61K38/19
CPC分类号： C07K14/52 , A61K38/00 , C07K2319/00 , C07K2319/55
摘要： The invention provides a fusion protein comprising at least four polypeptides, wherein the order of polypeptides from N-terminus to C-terminus are: a first polypeptide that comprises a sequence of amino acid residues from 41 to 56 of SEQ ID NO:2; a first spacer of 6-27 amino acid residues; a second polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix B residues 53-75 of SEQ ID NO:111; (b) IL-4 helix B residues 65-83 of SEQ ID NO:112; (c) IL-15 helix B residues 84-101 of SEQ ID NO:113; (d) GMCSF helix B residues 72-81 of SEQ ID NO:114; and (e) amino acid residues 69-84 of SEQ ID NO:2; a second spacer of 5-11 amino acid residues; a third polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix C residues 87-99 of SEQ ID NO:111; (b) IL-4 helix C residues 95-118 of SEQ ID NO:112; (c) IL-15 helix C residues 107-119 of SEQ ID NO:113; (d) GMCSF helix C residues 91-102 of SEQ ID NO:2; (e) amino acid residues 92-105 of SEQ ID NO:2; a third spacer of 3-29 amino acid residues; and a fourth polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix D residues 103-121 of SEQ ID NO:111; (b) IL-15 helix D residues 134-157 of SEQ ID NO:112; (c) IL-4 helix D residues 134-160 of SEQ ID NO:113; (d) GMCSF helix D residues 120-131 of SEQ ID NO:114; and (e) amino acid residues 135-148 of SEQ ID NO:2.
摘要翻译：本发明提供了包含至少四种多肽的融合蛋白，其中从N末端到C末端的多肽的顺序是：包含SEQ ID NO：2的41至56的氨基酸残基序列的第一多肽; 6-27个氨基酸残基的第一个间隔物; 包含选自以下的氨基酸残基序列的第二多肽：（a）SEQ ID NO：111的IL-2螺旋B残基53-75; （b）SEQ ID NO：112的IL-4螺旋B残基65-83; （c）SEQ ID NO：113的IL-15螺旋B残基84-101; （d）SEQ ID NO：114的GMCSF螺旋B残基72-81; 和（e）SEQ ID NO：2的氨基酸残基69-84; 第5个氨基酸残基的间隔物; 包含选自以下的氨基酸残基序列的第三多肽：（a）SEQ ID NO：111的IL-2螺旋C残基87-99; （b）SEQ ID NO：112的IL-4螺旋C残基95-118; （c）SEQ ID NO：113的IL-15螺旋C残基107-119; （d）SEQ ID NO：2的GMCSF螺旋C残基91-102; （e）SEQ ID NO：2的氨基酸残基92-105; 3-29个氨基酸残基的第三个间隔物; 和包含选自以下的氨基酸残基序列的第四多肽：（a）SEQ ID NO：111的IL-2螺旋D残基103-121; （b）SEQ ID NO：112的IL-15螺旋D残基134-157; （c）SEQ ID NO：113的IL-4螺旋D残基134-160; （d）SEQ ID NO：114的GMCSF螺旋D残基120-131; 和（e）SEQ ID NO：2的氨基酸残基135-148。

13. 发明公开

EP1555318A2 Hematopoietic cytokine receptor 失效
标题翻译：血细胞生成素Zytokin受体
公开(公告)号：EP1555318A2
公开(公告)日：2005-07-20
申请号：EP04030182.2
申请日：1997-05-19
申请人： ZymoGenetics, Inc.
发明人： Baumgartner, James W. , Foster, Donald C. , Grant, Francis J. , Sprecher, Cindy A.
IPC分类号： C12N15/12 , C07K14/715 , C12N15/62 , C07K16/28 , G01N33/68
CPC分类号： C07K14/715 , A61K38/00 , C07K2319/00
摘要： Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular ligand-binding domain of a cell-surface receptor that is expressed at high levels in lymphoid tissues, including B-cells and T-cells. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of lymphoid and myeloid cells in vitro and in vivo . Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo .
摘要翻译：公开了新型受体多肽，编码多肽的多核苷酸，以及相关组合物和方法。多肽包含细胞表面受体的细胞外配体结合结构域，其在淋巴组织（包括B细胞和T细胞）中以高水平表达。多肽可用于检测在体外和体内刺激淋巴样和骨髓细胞的增殖和/或发育的配体的方法。配体结合受体多肽也可用于在体外和体内阻断配体活性。

14. 发明授权

EP1881070B1 Human cytokine as ligand of the zalpha receptor and uses thereof 有权
标题翻译：人细胞因子为Z-α受体的配体和它们的用途
公开(公告)号：EP1881070B1
公开(公告)日：2012-10-03
申请号：EP07017344.8
申请日：2000-03-09
申请人： Zymogenetics, Inc.
发明人： Novak, Julie E. , Sprecher, Cindy A. , Gross, Jane A. , Nelson, Andrew J. , Dillon, Stacey R. , Hammond, Angela K.
IPC分类号： C12N15/19 , C07K14/52 , C12N15/62 , C12N15/85 , C07K16/24 , C12Q1/68 , G01N33/68 , A61K38/19
CPC分类号： C07K14/52 , A61K38/00 , C07K2319/00 , C07K2319/55

15. 发明授权

EP2230299B1 Novel cytokine ZCYTOR17 ligand 有权
标题翻译：新细胞因子配体ZCYTOR17
公开(公告)号：EP2230299B1
公开(公告)日：2011-12-07
申请号：EP10168189.8
申请日：2003-01-21
申请人： ZymoGenetics, Inc.
发明人： Sprecher, Cindy A. , Kuijper, Joseph L. , Dasovich, Maria M. , Grant, Francis J. , Hammond, Angela K. , Gross, Jane A. , Dillon, Stacey R. , Kuestner, Rolf
IPC分类号： C12N5/10 , C12N15/19 , C12N15/62 , C12N15/63 , C07K14/52 , C07K16/24 , G01N33/53 , G01N33/567 , A61K38/19 , A61K39/395 , C07K14/54
CPC分类号： C07K16/24 , A01K2217/05 , A61K38/00 , C07K14/47 , C07K14/52 , C07K2317/24

16. 发明公开

EP2230299A1 Novel cytokine ZCYTOR17 ligand 有权
标题翻译： Neuartiger Zytokin-ZCYTOR17-配体
公开(公告)号：EP2230299A1
公开(公告)日：2010-09-22
申请号：EP10168189.8
申请日：2003-01-21
申请人： ZymoGenetics, Inc.
发明人： Sprecher, Cindy A. , Kuijper, Joseph L. , Dasovich, Maria M. , Grant, Francis J. , Hammond, Angela K. , Gross, Jane A. , Dillon, Stacey R. , Kuestner, Rolf
IPC分类号： C12N5/10 , C12N15/19 , C12N15/62 , C12N15/63 , C07K14/52 , C07K16/24 , G01N33/53 , G01N33/567 , A61K38/19 , A61K39/395 , C07K14/54
CPC分类号： C07K16/24 , A01K2217/05 , A61K38/00 , C07K14/47 , C07K14/52 , C07K2317/24
摘要： There is provided an antibody or antibody fragment which specifically binds to a portion of SEQ ID NO:2, wherein said portion consists of between 30 and 100 contiguous amino acids of SEQ ID NO:2, and wherein said portion contains amino acids selected from the group consisting of: (a) amino acid residues 54 to 59 of SEQ ID NO: 2; (b) amino acid residues 129 to 134 of SEQ ID NO: 2; (c) amino acid residues 53 to 58 of SEQ ID NO: 2; (d) amino acid residues 35 to 40 of SEQ ID NO: 2; (e) amino acid residues 33 to 38 of SEQ ID NO: 2; (f) amino acid residues 114 to 119 of SEQ ID NO: 2; (g) amino acid residues 101 to 105 of SEQ ID NO: 2; (h) amino acid residues 126 to 131 of SEQ ID NO: 2; (i) amino acid residues 113 to 118 of SEQ ID NO: 2; and (j) amino acid residues 158 to 162 of SEQ ID NO:2.
摘要翻译：提供了与SEQ ID NO：2的一部分特异性结合的抗体或抗体片段，其中所述部分由SEQ ID NO：2的30-100个连续氨基酸组成，并且其中所述部分含有选自组成：（a）SEQ ID NO：2的氨基酸残基54至59; （b）SEQ ID NO：2的氨基酸残基129至134; （c）SEQ ID NO：2的氨基酸残基53至58; （d）SEQ ID NO：2的氨基酸残基35至40; （e）SEQ ID NO：2的氨基酸残基33至38; （f）SEQ ID NO：2的氨基酸残基114至119; （g）SEQ ID NO：2的氨基酸残基101至105; （h）SEQ ID NO：2的氨基酸残基126至131; （i）SEQ ID NO：2的氨基酸残基113至118; 和（j）SEQ ID NO：2的氨基酸残基158至162。

17. 发明授权

EP1749888B1 Soluble zalpha11 cytokine receptors 失效
标题翻译：可溶性细胞因子受体zalpfa11
公开(公告)号：EP1749888B1
公开(公告)日：2010-01-27
申请号：EP06011463.4
申请日：2001-04-03
申请人： ZymoGenetics, Inc.
发明人： Sprecher, Cindy A. , Novak, Julia E. , West, James, W. , Presnell, Scott R. , Holly, Richard D. , Nelson, Andrew J.
IPC分类号： C12N15/12 , C12N15/62 , C12N5/10 , C07K14/715 , C07K16/28 , A61K38/19
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7155 , C07K2317/73 , C07K2319/00

18. 发明公开

EP1881070A3 Human cytokine as ligand of the zalpha receptor and uses thereof 有权
标题翻译：人细胞因子作为zalpha受体的配体及其用途
公开(公告)号：EP1881070A3
公开(公告)日：2008-03-05
申请号：EP07017344.8
申请日：2000-03-09
申请人： Zymogenetics, Inc.
发明人： Novak, Julie E. , Sprecher, Cindy A. , Gross, Jane A. , Nelson, Andrew J. , Dillon, Stacey R. , Hammond, Angela K.
IPC分类号： C12N15/19 , C07K14/52 , C12N15/62 , C12N15/85 , C07K16/24 , C12Q1/68 , G01N33/68 , A61K38/19
CPC分类号： C07K14/52 , A61K38/00 , C07K2319/00 , C07K2319/55
摘要： The invention provides a fusion protein comprising at least four polypeptides, wherein the order of polypeptides from N-terminus to C-terminus are: a first polypeptide that comprises a sequence of amino acid residues from 41 to 56 of SEQ ID NO:2; a first spacer of 6-27 amino acid residues; a second polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix B residues 53-75 of SEQ ID NO:111; (b) IL-4 helix B residues 65-83 of SEQ ID NO:112; (c) IL-15 helix B residues 84-101 of SEQ ID NO:113; (d) GMCSF helix B residues 72-81 of SEQ ID NO:114; and (e) amino acid residues 69-84 of SEQ ID NO:2; a second spacer of 5-11 amino acid residues; a third polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix C residues 87-99 of SEQ ID NO:111; (b) IL-4 helix C residues 95-118 of SEQ ID NO:112; (c) IL-15 helix C residues 107-119 of SEQ ID NO:113; (d) GMCSF helix C residues 91-102 of SEQ ID NO:2; (e) amino acid residues 92-105 of SEQ ID NO:2; a third spacer of 3-29 amino acid residues; and a fourth polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix D residues 103-121 of SEQ ID NO:111; (b) IL-15 helix D residues 134-157 of SEQ ID NO:112; (c) IL-4 helix D residues 134-160 of SEQ ID NO:113; (d) GMCSF helix D residues 120-131 of SEQ ID NO:114; and (e) amino acid residues 135-148 of SEQ ID NO:2.
摘要翻译：本发明提供了包含至少四种多肽的融合蛋白，其中从N端到C端的多肽顺序为：包含SEQ ID NO：2的41至56位氨基酸残基序列的第一多肽; 第一个6-27个氨基酸残基的间隔区; 包含选自以下的氨基酸残基序列的第二多肽：（a）SEQ ID NO：111的IL-2螺旋B残基53-75; （b）SEQ ID NO：112的IL-4螺旋B残基65-83; （c）SEQ ID NO：113的IL-15螺旋B残基84-101; （d）SEQ ID NO：114的GMCSF螺旋B残基72-81; 和（e）SEQ ID NO：2的氨基酸残基69-84; 5-11个氨基酸残基的第二间隔区; 包含选自以下的氨基酸残基序列的第三多肽：（a）SEQ ID NO：111的IL-2螺旋C残基87-99; （b）SEQ ID NO：112的IL-4螺旋C残基95-118; （c）SEQ ID NO：113的IL-15螺旋C残基107-119; （d）SEQ ID NO：2的GMCSF螺旋C残基91-102; （e）SEQ ID NO：2的氨基酸残基92-105; 3-29个氨基酸残基的第三个间隔区; 和第四多肽，其包含选自以下的氨基酸残基序列：（a）SEQ ID NO：111的IL-2螺旋D残基103-121; （b）SEQ ID NO：112的IL-15螺旋D残基134-157; （c）SEQ ID NO：113的IL-4螺旋D残基134-160; （d）SEQ ID NO：114的GMCSF螺旋D残基120-131; 和（e）SEQ ID NO：2的氨基酸残基135-148。

19. 发明公开

EP1857466A3 Soluble interleukin-20 receptor 有权
标题翻译：可溶性白介素20受体
公开(公告)号：EP1857466A3
公开(公告)日：2008-02-13
申请号：EP07012370.8
申请日：2000-12-22
申请人： ZymoGenetics, Inc.
发明人： Foster, Donald C. , Xu, Wenfeng , Madden, Kare L. , Kelly, James D. , Sprecher, Cindy A. , Brandt, Cameron S. , Rixon, Mark W. , Presnell, Scott R. , Fox, Brian A.
IPC分类号： C07K14/715 , C12N15/62 , C12N15/09 , C07K16/00 , A61P17/06
CPC分类号： C07K14/7056 , A61K38/00 , C07K2319/00
摘要： A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.

20. 发明公开

EP1743648A1 Method for treating inflammation 有权
标题翻译： Verfahren zur Behandlung vonEntzündungen
公开(公告)号：EP1743648A1
公开(公告)日：2007-01-17
申请号：EP06006242.9
申请日：2000-12-22
申请人： ZymoGenetics, Inc.
发明人： Thompson, Penny , Foster, Donald C. , Wenfeng, Xu , Madden, Karen L. , Kelly, James D. , Sprecher, Cindy A. , Blumberg, Hal , Eagen, Maribeth A. , Jaspers, Stephen R. , Chandrasekher, Jasmin A. , Novak, Julia E.
IPC分类号： A61K38/17 , C07K14/54 , C07K19/00 , A61P1/00 , A61P11/06 , A61P19/02 , A61P35/00 , A61P37/00 , A61P31/00 , C07K14/715
CPC分类号： C07K14/7155 , A61K38/00 , A61K38/20 , C07K16/244 , C07K2319/30
摘要： The use is provided of a soluble receptor that binds to an IL-20 polypeptide, wherein the IL-20 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8 and 9, for the manufacture of a medicament for treating an inflammatory disease, wherein said soluble receptor comprises: a first subunit, said first subunit comprising an amino acid sequence selected from SEQ ID NOs: 11, 12, 55, 63 and 65, or a fragment thereof that binds to an IL-20 polypeptide; and a second subunit, said second subunit comprising an amino acid sequence selected from SEQ ID NOs: 14, 15, 19, 59, 61, 67, 68 and 69, or a fragment thereof that binds to an IL-20 polypeptide; wherein said inflammatory disease is an inflammatory lung disease, an inflammatory bowel disease, systemic lupus erythematosis, rheumatoid arthritis, idiopathic pulmonary fibrosis, septic shock or multiple organ failure.
摘要翻译：提供了与IL-20多肽结合的可溶性受体的用途，其中IL-20多肽包含选自下组的氨基酸序列：SEQ ID NO：1,2,3,4,5,6， 7,8和9，用于制备用于治疗炎性疾病的药物，其中所述可溶性受体包含：第一亚基，所述第一亚基包含选自SEQ ID NO：11,12,55,63的氨基酸序列和 65或其与IL-20多肽结合的片段; 和第二亚基，所述第二亚单位包含选自SEQ ID NO：14,15,19,59,61,67,68和69的氨基酸序列或其与IL-20多肽结合的片段; 其中所述炎性疾病是炎症性肺病，炎症性肠病，系统性红斑狼疮，类风湿性关节炎，特发性肺纤维化，败血性休克或多器官衰竭。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式